# A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

> **NCT04578548** · PHASE2 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 66 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease

## Interventions

- **DRUG:** GLPG2737
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04578548
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-10
- **Primary completion:** 2022-12-14
- **Final completion:** 2023-04-04
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** The study was early terminated due to lack of efficacy.
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578548, "A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04578548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*